In our research lab, we are committed to spearheading advancements in in-vivo magnetic resonance imaging (MRI), spectroscopy (MRS), and the convergence of advanced MRI methods with AI/DL techniques. Central to our endeavors is the innovation of non-invasive imaging for several cancers, prominently kidney tumors, prostate cancer, breast cancer, glioma, TBI, and the challenges posed by dementia.

Our investigations delve into the complex interplay of angiogenesis, metabolism, and tumor development. Leveraging state-of-the-art techniques such as radiogenomics, radiomics, and machine learning, we maximize the capabilities of multiparametric MRI (mpMRI), MR spectroscopy, arterial spin labeling (ASL), and cutting-edge diffusion MR techniques across varied cancer categories. Beyond mere innovation, our goal is to ensure the smooth transition of these MR methods into real-world clinical scenarios.

While cancer research forms our foundation, we are branching out, examining the symbiotic relationship between advanced MRI methods and transfer learning, especially in the context of Alzheimer's disease research. Our aspiration extends beyond understanding – we aim to diagnose and pave the way for effective management of this debilitating neurological condition.

Our vision is unwavering: to pioneer early detection and minimize the invasiveness of cancer diagnostic procedures. We remain resolute in our mission to extend the frontiers of scientific understanding, mentor the next wave of research talent, and make a tangible impact in the overarching healthcare domain. 

Embracing a multidisciplinary approach, we accentuate personalized medical strategies achieved through the continuous advancement and practical application of MR techniques. Rooted in the pillars of collaboration and innovation, we are set on redefining the panorama of dementia and cancer imaging, with the ultimate goal of enhancing patient care and outcomes.